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Purpose: This article examines the current status of
translational science for Alzheimer’s disease (AD)
drug discovery by using an analytical model of
technology maturation. Previous studies using this
model have demonstrated that nascent scientiﬁc
insights and inventions generate few successful leads
or new products until achieving a requisite level of
maturity. This article assessed whether recent failures
and successes in AD research follow patterns of
innovation observed in other sectors.
Methods: The bibliometric-based Technology Innova-
tion Maturation Evaluation model was used to quantify
the characteristic S-curve of growth for AD-related
technologies, including acetylcholinesterase, N-methyl-D-
aspartate (NMDA) receptors, B-amyloid, amyloid pre-
cursor protein, presenilin, amyloid precursor protein
secretases, apolipoprotein E4, and transactive response
DNA binding protein 43 kDa (TDP-43). This model
quantiﬁes the accumulation of knowledge as a metric for
technological maturity, and it identiﬁes the point of
initiation of an exponential growth stage and the point
at which growth slows as the technology is established.
Findings: In contrast to the long-established acetyl-
cholinesterase and NMDA receptor technologies,This research was presented, in part, at a conference (“Learning From
Cancer to Advance Neurodegeneration Drug Discovery and Develop-
ment”) presented by the New York Academy of Sciences, June 2015.
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August 2015we found that amyloid-related technologies reached
the established point only after 2000, and that the
more recent technologies (eg, TDP-43) have not yet
approached this point. The ﬁrst approvals for new
molecular entities targeting acetylcholinesterase and the
NMDA receptor occurred an average of 22 years after
the respective technologies were established, with only
memantine (which was phenotypically discovered)
entering clinical trials before this point. In contrast,
the 6 lead compounds targeting the formation of
amyloid plaques that failed in Phase III trials between
2009 and 2014 all entered clinical trials before the
respective target technologies were established.
Implications: This analysis suggests that AD drug
discovery has followed a predictable pattern of inno-
vation in which technological maturity is an important
determinant of success in development. Quantitative
analysis indicates that the lag in emergence of new
products, and the much-heralded clinical failures of
recent years, should be viewed in the context of the
ongoing maturation of AD-related technologies.
Although these technologies were not sufﬁciently
mature to generate successful products a decade ago,
they may be now. Analytical models of translational
science can inform basic and clinical research results as
well as strategic development of new therapeutic
products. (Clin Ther. 2015;37:1643–1651) & 2015
The Authors. Published by Elsevier HS Journals, Inc.Scan the QR Code with your phone to obtain
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INTRODUCTION
Alzheimer’s disease (AD) has proved to be a challeng-
ing target for drug discovery. It has been 12 years
since the last approval of a new molecular entity
(NME) aimed at treating the core symptom complex
of AD. Moreover, there is a paucity of both validated
drug targets and advanced-stage clinical candidates
with the potential to modify the essential pathogenesis
of the disease or its associated disabilities.
The challenge has been exacerbated in recent years
by the Phase III failures of several lead compounds
(most recently, bapineuzumab and solanezumab in
2012 and gammagard in 2013) designed to reduce
β-amyloid plaque formation. These high-proﬁle failures
led many to conclude that β-amyloid may not be a
viable target for AD.1–7 The subsequent successes of a
Phase I trial with aducanumab in prodromal (or mild)
AD,8 as well as optimism regarding the ongoing trial of
crenezumab in a Columbian cohort of early-onset AD,9
have rekindled interest in β-amyloid as a drug target.10
The meager product pipeline and limited number of
validated targets for drug discovery seems incongru-
ous with the dramatic advances in understanding AD
that have come from positional cloning, genomics,
transgenic disease models, positron emission tomog-
raphy scanning, and sophisticated biomarkers. Per-
haps the most important pathologic insight occurred
when the protein comprising the amyloid plaques was
identiﬁed as β-amyloid,11 a cleaved form of the known
genetic risk factor, amyloid precursor protein (APP).12
It was hypothesized that the accumulation of β-
amyloid plays a central role in the pathogenesis of
the disease and its symptoms. Dubbed the “amyloid
hypothesis,” targeting β-amyloid with immunothera-
pies to reduce amyloid plaques has become a domi-
nant strategy for treating AD.13,14
Other targets have also been identiﬁed. In addition,
drug discovery efforts have focused on APP secretase
enzymes, which are responsible for cleavage of APP to
form β-amyloid.15 Presenilin 1 and 2, components of
λ-secretase, have also been identiﬁed as genetic risk
factors for the disease16 and are a signiﬁcant focus of
interest. The neuroﬁbrillary tangles, which are a
characteristic pathologic feature in diseased brains,
have been identiﬁed as tau protein, a microtubule-1644binding protein that stabilizes the long microtubules
involved in structural support of neurons.17 AD
research continues to identify putative pathways that
impact the pathogenesis or core symptoms of the
disease and propose novel targets for interventions.
Five NMEs have been approved for treating the
core symptom complex of AD. These compounds,
however, were not generated from recent molecular
insights but originated from older research in other
ﬁelds. Speciﬁcally, NMEs that target acetylcholines-
terase (AChE)18 or N-methyl-D-aspartate (NMDA)
receptors19 were discovered through research on these
neurotransmitter pathways and were only later applied
to AD therapy. Moreover, the most common genetic
risk factor for both sporadic and familial forms of AD,
the apolipoprotein E4 allele,20 was ﬁrst described as a
risk factor for cardiovascular disease and is now
considered an important biomarker in AD. In fact, 1
of the important strategies for current research is
repurposing drugs from other indications.
The goal of the present article was to examine the
status of innovation in AD by using an analytical
model for the maturation of technology and the
relationship between technological maturation and
successful product development. We assessed whether
the paucity of therapeutic products and recurrent
failure of lead compounds arising from recent scien-
tiﬁc advances are consistent with the time course of
translational science observed in other therapeutic
areas. Speciﬁcally, an analytical model of technology
maturation was used to determine whether the recent
failures of drugs designed to reduce β-amyloid should
be interpreted as invalidating the amyloid hypothesis
or whether amyloid-related technologies are not yet
sufﬁciently mature to expect efﬁcient generation of
successful lead and therapeutic products.
PATTERNS OF INNOVATION IN
BIOPHARMACEUTICAL DEVELOPMENT
Research on innovation in different technology sectors
suggests that technologies mature through a character-
istic, sigmoid growth cycle (S-curve) (Figure 1) and
that the ability to generate successful products is
predictably related to technology maturity.21–26 The
key feature of the technology S-curve is a stage of
exponential growth sparked by a scientiﬁc insight or
invention. This “initiation” event is followed by
exponential advances that continue until limits are
encountered and growth slows. At this point, theVolume 37 Number 8
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Figure 1. Quantitative model of the technology
growth S-curve. The technology
growth cycle is modeled as an expo-
nentiated logistic function (solid green
line) fit to cumulative publications (N)
in a PubMed search. The technology
initiation point (Ti) is the point of
maximum acceleration (max d2N/dt2
[dashed green line]) or the beginning
of an exponential growth stage. The
technology established point (Te) is
the point of maximum slowing (min
d2N/dt2 [dashed green line]) or the
end of exponential growth.
J.M. Beierlein et al.technology is considered “established.” Although new
insights and inventions offer the promise of new product
opportunities, nascent technologies commonly fail to
generate products that can meet the standards set by
previous, established technologies.21,22 Only as the nas-
cent technologies mature to the point of being established
are they able to generate state-of-the-art products that
can satisfy prevailing performance standards.
Previous studies have applied these principles to
biopharmaceutical development by using a
bibliometric-based analytical model for technology
maturation termed the Technology Innovation Matu-
ration Evaluation model.25,27–29 From these studies, we
have shown that the accumulation of knowledge
regarding speciﬁc biotechnologies, drug classes, or drug
targets, as measured by the cumulative number ofAugust 2015publications in PubMed, follows a S-curve growth
pattern that can be modeled with an exponentiated
logistic function (Figure 1). Using a nonlinear least
squares ﬁt of this function to the cumulative
publication counts, we identify an initiation point (Ti)
corresponding to the point of maximum acceleration of
publication activity (max d2N/dt2), and an established
point (Te) corresponding to the point of maximum
slowing of publication activity (min d2N/dt2).24 The
analytical method is described in more detail in the
Supplemental Appendix (see the online version at
http://dx.doi.org/10.1016/j.clinthera.2015.07.003).
Validation studies revealed that the derived Ti corre-
sponds to seminal events in the scientiﬁc literature that
enabled exponential growth of the ﬁeld25,27 (Additional
studies outside of the references have been reported by
Walsh et al., personal communication). More impor-
tantly, our studies show that biopharmaceutical develop-
ment follows the pattern observed in other technology
sectors, with few successful projects being generated by
nascent or growing stage technologies, and most new
products arising from established-stage technolo-
gies.25,28,29 Well-known examples of this phenomenon
include monoclonal antibodies, gene therapies, and
nucleotide therapies, in which there were hundreds of
clinical failures during the 420 years before the ﬁrst
successful products were approved. Analytical studies
show that these approvals occurred only after these
technologies passed the established point.25,27 Similarly,
a study of 100 NMEs approved by the US Food and
Drug Administration from 2010 to 2013 showed that
the ﬁrst approvals of targeted and biological NMEs
occurred an average of 14 years after knowledge of the
target passed the established point, with only 2 of 82
NMEs being approved before this point. It was also
observed that the large majority (58 of 82) of approved
NMEs only began clinical trials after the established
point, and the clinical development time for these
products was signiﬁcantly shorter (8.5 vs 11.6 years;
P o 0.001) than for those that entered trials before the
technology was established. Thus, drug development
becomes signiﬁcantly more efﬁcient once the associated
technology passes the established point. Finally, our data
suggest that the time between a scientiﬁc insight, or
invention that gives rise to a new area of research, to
approval of products based on this technology is 36
years,29 an interval similar to that described by others
looking at the elapsed time between seminal publications
and drug approvals.301645
Clinical TherapeuticsMODELING TECHNOLOGIES FOR AD
DISCOVERY
The Technology Innovation Maturation Evaluation
model was used to examine the maturation of technol-
ogies associated with AD drug discovery. This analysis
included novel targets emerging from AD research
that have yet to generate therapies, as well as older
technologies associated with approved therapies such
as AChE and NMDA receptors (Figure 2). The
PubMed search strategy and a glossary of search
terms are provided in Supplemental Table I (see the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.07.003). For most of the technologies examined,
the accumulation of publications exhibited a discer-
nable exponential stage of growth and could be mod-
eled with the best-ﬁt, exponentiated logistic function.4
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Figure 2. Technology Innovation Maturation Evaluation
associated targets and technologies. The squar
for each target or technology, whereas the corr
model. Predicted year of the technology estab
diamonds indicate year of new molecular entity
green diamond indicates year of approval for N
Due to log-scale, disorder at the lower en
publications between the model and actual p
β-amyloid target curves. ApoE ¼ apolipoprote
APP ¼ amyloid precursor protein.
1646Of the 5 NMEs currently approved for AD, 4
target AChE, and 1 targets the NMDA receptor (see
Supplemental Table II in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.07.003). Both tar-
gets exhibit a characteristic, sigmoid growth curve
(Figure 2A). For AChE, the initiation point was
1931, corresponding to early studies showing modu-
lation of cholinergic functions with synthetic
derivatives of natural alkaloids in 1930s18; expon-
ential growth reached an established point in 1973.
For NMDA receptors, the initiation point was 1971,
corresponding to recognition of the role of glutamate in
synaptic transmission in 197231 and identiﬁcation of
various excitatory receptors in 1968 and 1974.32,33
Exponential growth of NMDA receptors reached an
established point in 1993.Acetylcholinesterase
NMDA_receptors
Tau
Presenilns
APP_secretases
AD_and_amyloid
Amyloid_plaques
APP
TDP-43
ApoE
2000
2010
2010
2000
(TIME) models of various Alzheimer’s disease (AD)-
es indicate the log of the cumulative publication data
esponding colored line indicates the TIME projection
lished point is indicated by the plus sign. The blue
approval for acetylcholinesterase inhibitors, and the
-methyl-D-aspartate (NMDA) receptor antagonists.
d of curve only represents a difference of 10
ublications. (A) Nonamyloid target curves; and (B)
in; TDP-43 ¼ TAR DNA-binding protein of 43 kDa;
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J.M. Beierlein et al.None of these 5 products was approved before
their respective technology passed the establis-
hed point (Figure 3), with an average time from the
established point to NME approval of 22 years. Only
1 of these products, memantine, entered clinical trials
before the established point. It is notable that
memantine was classiﬁed by Swinney and Anthony34
as having been discovered by phenotypic screening for
a non-AD target rather than as a targeted screen. This
compound was, in fact, ﬁrst synthesized in 1968,
before discovery of the NMDA receptor. The early
clinical entry date for this compound is consistent with
the mode of discovery that was not predicated on
knowledge of the target.
It is also notable that tacrine, the ﬁrst of the AChE
inhibitors to enter clinical trials and achieve approval,
is no longer on the market. The 3 remaining AChE
inhibitors entered clinical trials, on average, 17 years
after the established point and were approved 26 years
after this point. Although the number of approved
NMEs for treating AD is too small for statistical
analysis, these results suggest that the development of
these products is consistent with quantitative patterns
observed previously for drugs against other diseases.35
Identiﬁcation of publications regarding β-amyloid
in PubMed is complicated by the original use of the
term “amyloid” to describe iodine-positive deposits.
To identify publications speciﬁc to the AD-associated1930
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Figure 3. Time lines of Alzheimer’s disease (AD) tec
Evaluation modeled dates of technology initi
shown as a linear progression for AD targets.
approval by the US Food and Drug Administr
their specified target. From earliest clinical tri
(2) memantine; (3) rivastigmine; (4) donep
aspartate; ApoE ¼ apolipoprotein; APP ¼ am
August 2015amyloid protein, we searched for “amyloid AND
Alzheimer’s disease,” “amyloid plaques,” or “amyloid
precursor protein” (see Supplemental Table I in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.07.003). All 3 analyses of β-amyloid terms
identiﬁed an initiation point between 1964 and 1967
(Figure 2B), corresponding to the immunologic
identiﬁcation of an amyloid protein in 1967.36 The
technology growth curves for APP secretases identiﬁed
an initiation point of 1988, corresponding to the
cloning and sequencing of the APP gene in 1987.12
Presenilin is a component of the APP secretase, γ-
secretase, whose connection to AD was discovered
through genetic linkage analysis in AD cohorts.37 The
technology growth curve for presenilin indicates an
initiation point of 1983, corresponding to the ﬁrst
linkage maps of the human genome 1980 and
198538,39 and identiﬁcation of AD cohorts. Looking
broadly at β-amyloid, as well as targets known to be
involved in generating amyloid plaques such as APP
secretases and presenilins, our analysis suggests that
each of these technology curves reached the estab-
lished stage only in the early 2000s.
Three other analyses are also shown (Figure 2A).
The technology growth curve for apolipoprotein E4
indicates an initiation point of 1967, which
corresponds with the ﬁrst separation of apoli-
poproteins from cholesterol40,41 in 1968 and 1969.Acetylcholinesterase
NMDA receptors
Tau
2010990
Amyloid plaques
AD and amyloids
APP secretases
APP
Presenilins
ApoE
hnologies. The Technology Innovation Maturation
ation points, and technology established points are
The dashed lines indicate time from clinical entry to
ation for new molecular entities and are placed over
al entry, the new molecular entities are: (1) tacrine;
ezil; and (5) galantamine. NMDA ¼ N-methyl-D-
yloid precursor protein.
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Table. Selected β-amyloid therapies in clinical
trials.
Drug Name Mechanism of Action
Phase
I Start
Tramiprosate Aβ aggregation inhibitor 1999
Tarenﬂurbil γ-secretase modulator 2002
Semagacestat γ-secretase inhibitor 2004
Bapineuzumab Humanized mAB direct
at aa 1-5 of Aβ peptide
2004
Solanezumab Humanized mAB direct at
aa 16-24 of Aβ peptide
2006
Gammagard* Immunoglobulin 2009
Crenezumab Human recombinant
anti-β amyloid mAB
2008
Aducanumab Human recombinant
anti-β amyloid mAB
2011
Aβ ¼ β-amyloid; aa ¼ amino acids; mAB ¼ monoclonal
antibody.
The ﬁrst 6 products and their targets were identiﬁed from
Karran and Hardy47 as targeting the formation of
amyloid plaques. These products completed Phase III
trials between 2009 and 2014, failing to meet their
clinical end points. The last 2 products are
immunotherapies designed to reduce β-amyloid
therapies and currently in clinical trials.
*Approved product for immunodeﬁciency, repurposed
for Alzheimer’s disease and entered clinical trials for
Alzheimer’s disease in Phase III.
Clinical TherapeuticsThe technology growth curve for tau protein indicates
an initiation point of 1968, which corresponds with
the ﬁrst isolation of proteins bound to microtubulins
in 1967 and 1968.42,43 Of particular interest is the
technology growth curve for the transactive response
DNA-binding protein of 43 kDa (TDP-43), a protein
ﬁrst identiﬁed for its association with amyotrophic
lateral sclerosis and more recently associated with
AD.44–46 Growth of publications related to TDP-43
could not be modeled with the sigmoid function.
Closer analysis suggests that this technology is still
in the exponential, growing stage of the growth cycle
and has not yet approached the established stage.
INTERPRETING CLINICAL FAILURES OF
DRUG-TARGETING AMYLOID PLAQUES
Six products targeting the formation of amyloid
plaques completed Phase III trials between 2009 and
2014 but failed to meet their clinical end points.47 The
high-proﬁle clinical failures of lead compounds de-
signed to clear amyloid plaques by passive immuniza-
tion (eg, bapineuzumab),48 as well as drugs designed
to block improper cleavage of APP by inhibiting
secretase (eg, semagacestat),49 raised concerns about
the amyloid hypothesis and the potential for treating
AD by targeting amyloid plaque formation.
The table shows the Phase I start dates for 5 of
these products, ranging from 1999 to 2006. The sixth,
gammagard, entered clinical trials for AD in Phase III
after being repurposed from its original indication for
immunodeﬁciency disorder in 2005. All 6 of these
NMEs entered clinical development before the point
at which amyloid-related technologies would be con-
sidered established. In contrast, for all targeted and
biological products approved from 2010 to 2013, the
clinical entry point averaged 5 years after the estab-
lished point,29 and the 3 AChE inhibitors on the
market entered clinical development 17 years after
AChE technologies passed this point.
The recent success of aducanumab in a Phase Ib
trial for prodromal (or mild) AD8 and crenezumab in
a Columbian cohort of early-onset AD9 present a
different picture. Aducanumab was ﬁrst used in the
clinic in 2011, while crenezumab was ﬁrst used in
2008. These dates are listed in the table. Coupled with
new reports supporting the importance of β-amyloid
in AD50,51 and endorsement of β-amyloid as a diag-
nostic tool in clinical trials by the US Food and Drug
Administration,52,53 the ﬁeld appears to be moving1648toward more effectively operationalizing the amyloid
hypothesis. We believe it is signiﬁcant that these
events are occurring at a time when analytical models
of technology maturation suggest that these technol-
ogies have passed the established point.CONCLUSIONS
The present analysis suggests that AD drug discovery
has followed predictable patterns of innovation. All of
the approved targeted and biological NMEs, and the
recent clinical successes targeting amyloid plaques, have
arisen from established technologies, whereas the often-
heralded failures reﬂect less mature technologies.
It is often argued that the high failure rate of lead
compounds in clinical trials reﬂects the innate
complexity of biological systems. Certainly AD is
complex. In this context, it is not surprising that the
accumulation of knowledge, which our model usesVolume 37 Number 8
J.M. Beierlein et al.as a metric of technology maturation, reduces the
apparent complexity and improves the efﬁciency of
development.
Why does the established point, corresponding to a
slowing of publication activity, predict the efﬁciency
of clinical development? We have closely examined
several examples, each of which involves distinct,
tactical issues. For monoclonal antibodies, the path
to maturity involved sequential growth from murine
antibodies to chimeric, humanized, and ﬁnally human
forms25 that provided greater safety, bioavailability,
and efﬁcacy. For gene therapies, maturation involved
emergence of a series of novel viral vectors as well as
critical innovations designed to improve safety, gene
expression, and production.25,27 For protein kinase
inhibitors, maturation involved growing recognition
of the large number of protein kinases and a change
in focus of drug discovery from speciﬁcity to class
effects.54 Although more research needs to be
conducted to understand the dynamics underlying
the predictable technology growth pattern, we
suggest that the slowing may be an early indicator
that uncertainties are reduced, and fewer new research
questions emerge.
In the case of the amyloid-related targets, the failed
clinical trials of recent years have contributed substan-
tively to the maturation of these technologies. Data
from the APP secretase inhibitor trials have increased
knowledge regarding the selectivity of the target.55
Immunotherapy trials have informed understanding
of their potential adverse effects.56 Previous studies
have also informed the use of biomarkers, which are
increasingly accepted by regulatory agencies.57 Perhaps
the most important growth has come from advances in
the design of clinical trials. Clinical investigators now
have a better understanding of which patient
populations are most likely to respond to speciﬁc
interventions,58 better tools for characterizing clinical
end points,59 and new regulatory pathways for more
efﬁcient development.60 Although key technologies in
this ﬁeld were not sufﬁciently mature to generate
successful products a decade ago, they may be now.
Analytical models of translational science can inform
basic and clinical research results and strategic
development of new therapeutic products.
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SUPPLEMENTAL APPENDIX. TECHNOLOGY
INNOVATION MATURATION EVALUATION
MODEL.
Derivation and validation of the analytical model have
been described in detail by Walsh. Brieﬂy, an expo-
nentiated logistic function was used to model publica-
tion growth:
N¼Lð
1
1þ erðtt0 Þ
Þ
which also has the form
log N¼ log L
1þerðtt0Þ
where N is the number of publications, L is the
presumed upper limit of publications, r is the
growth rate, t is time, and t0 is midpoint of exponential
growth.
This asymmetric sigmoidal function exhibits the
common logistic sigmoid function over log scales. This
gives it property of having a symmetric growth phase
that is exponential on average. The initiation and
established points, representing the beginning and
end of exponential growth or logN’’(t)max,min
(Figure 1) can be analytically determined by:
Established; nitiation¼ t0
a coshð2Þ
r
The parameters were ﬁt to time series publication
data using a nonlinear least squares implemen-
tation of the Levenberg-Marquardt algorithm in
Python, which can be found at http://lmﬁt.github.io/
lmﬁt-py/.
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Supplemental Table I. Alzheimer’s disease (AD) targets, PubMed search terms, and technology initiation (Ti)
and establishment (Te) points.*
Target/
Technology PubMed Search Terms Ti Te
Acetylcholi-
nesterase
“acetylcholinesterase”[MeSH terms] 1931 1973
NMDA
receptors
“receptors, n-methyl-d-aspartate”[MeSH Terms] 1971 1993
AD and
amyloid
(“alzheimer disease”[MeSH Terms] OR “dementia”[MeSH
Terms] OR “mild cognitive impairment”[MeSH Terms])
AND “amyloid”[MeSH Terms]
1964 2003
Amyloid
plaques
plaque, amyloid[MeSH Terms] OR (“plaque”[All Fields] AND
“amyloid”[All Fields]) OR “amyloid plaque”[All Fields] OR
(“amyloid"[All Fields] AND “plaques”[All Fields]) OR
“amyloid plaques”[All Fields]
1966 2000
APP “amyloid beta-protein precursor”[MeSH Terms] 1967 2002
APP secretases “amyloid precursor protein secretases”[MeSH Terms] 1988 2005
Tau “tau proteins”[MeSH Terms] 1968 2004
ApoE “apolipoproteins e”[MeSH Terms] 1967 1997
Presenilin “presenilins”[MeSH Terms] 1982 2000
TDP-43 “protein TDP-43”[Supplementary Concept] OR “protein
TDP-43”[All Fields] OR “tdp 43”[All Fields]
NA NA
NMDA ¼ N-methyl-d-aspartate; APP ¼ amyloid precursor protein; ApoE ¼ apolipoprotein E; NA ¼ not applicable.
*PubMed searches were performed by using Medical Subject Heading (MeSH) terms, when possible. Searches for
“amyloid”[MeSH] retrieved large numbers of publications unrelated to AD, reﬂecting historical use of the amyloid term
to describe various iodine staining deposits other than AD-related protein. Searches for "amyloid plaques"[MeSH] resulted
in 3.5 times fewer papers. The broader search terms used provided more comprehensive retrieval of relevant papers. TAR
DNA-binding protein of 43 kDa (TDP-43) had no corresponding MeSH term.
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Supplemental Table II. Alzheimer’s disease drugs approved by the US Food and Drug Administration and
analysis with Technology Innovation Maturation Evaluation model results.
NME Target Ti Te CE AP CE-Te AP-Te AP-CE Te-Ti
Tacrine AChE 1931 1973 19831,2 1993 10 20 10 42
Donepezil AChE 1931 1973 19903 1996 17 23 6 42
Rivastigmine AChE 1931 1973 19903 2000 17 27 10 42
Galantamine AChE 1931 1973 19914 2001 18 28 10 42
Memantine NMDA 1971 1993 19865 2003 7 10 17 22
NME ¼ new molecular entity; Ti ¼ technology initiation; Te ¼ technology establishment; CE ¼ Clinical Entry; AP ¼
Approval; AChE ¼ acetylcholinesterase; NMDA ¼ N-methyl-d-aspartate.
AP dates from the US Food and Drug Administration were retrieved from the Drugs@FDA Web site. CE dates were identiﬁed
by the earliest clinical publication in PubMed or in PharmaProjects, whichever was earlier. Ti and Te were generated by using
the Technology Innovation Maturation Evaluation model.
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